Publication:
Good practice recommendations on add-ons in reproductive medicine

dc.contributor.coauthorLundin, K.
dc.contributor.coauthorESHRE Addons Working Grp, J. G.
dc.contributor.coauthorBentzen, J. G.
dc.contributor.coauthorEbner, T.
dc.contributor.coauthorHarper, J.
dc.contributor.coauthorLe Clef, N.
dc.contributor.coauthorMoffett, A.
dc.contributor.coauthorNorcross, S.
dc.contributor.coauthorPolyzos, N. P.
dc.contributor.coauthorRautakallio-Hokkanen, S.
dc.contributor.coauthorSfontouris, I
dc.contributor.coauthorSermon, K.
dc.contributor.coauthorVermeulen, N.
dc.contributor.coauthorPinborg, A.
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorBozdağ, Gürkan
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-01-19T10:29:31Z
dc.date.issued2023
dc.description.abstractSTUDY QUESTION: Which add-ons are safe and effective to be used in ART treatment? SUMMARY ANSWER: Forty-two recommendations were formulated on the use of add-ons in the diagnosis of fertility problems, the IVF laboratory and clinical management of IVF treatment. WHAT IS KNOWN ALREADY: The innovative nature of ART combined with the extremely high motivation of the patients has opened the door to the wide application of what has become known as 'add-ons' in reproductive medicine. These supplementary options are available to patients in addition to standard fertility procedures, typically incurring an additional cost. A diverse array of supplementary options is made available, encompassing tests, drugs, equipment, complementary or alternative therapies, laboratory procedures, and surgical interventions. These options share the common aim of stating to enhance pregnancy or live birth rates, mitigate the risk of miscarriage, or expedite the time to achieving pregnancy. STUDY DESIGN, SIZE, DURATION: ESHRE aimed to develop clinically relevant and evidence-based recommendations focusing on the safety and efficacy of add-ons currently used in fertility procedures in order to improve the quality of care for patients with infertility. PARTICIPANTS/MATERIALS, SETTING, METHODS: ESHRE appointed a European multidisciplinary working group consisting of practising clinicians, embryologists, and researchers who have demonstrated leadership and expertise in the care and research of infertility. Patient representatives were included in the working group. To ensure that the guidelines are evidence-based, the literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, recommendations were based on the professional experience and consensus of the working group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 46 independent international reviewers. A total of 272 comments were received and incorporated where relevant. MAIN RESULTS AND THE ROLE OF CHANCE: The multidisciplinary working group formulated 42 recommendations in three sections; diagnosis and diagnostic tests, laboratory tests and interventions, and clinical management. LIMITATIONS, REASONS FOR CAUTION: Of the 42 recommendations, none could be based on high-quality evidence and only four could be based on moderate-quality evidence, implicating that 95% of the recommendations are supported only by low-quality randomized controlled trials, observational data, professional experience, or consensus of the development group. WIDER IMPLICATIONS OF THE FINDINGS: These guidelines offer valuable direction for healthcare professionals who are responsible for the care of patients undergoing ART treatment for infertility. Their purpose is to promote safe and effective ART treatment, enabling patients to make informed decisions based on realistic expectations. The guidelines aim to ensure that patients are fully
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue11
dc.description.openaccessGreen Published, hybrid
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipThe meetings and technical support for this project were funded by the European Society of Human Reproduction and Embryology.
dc.description.volume38
dc.identifier.doi10.1093/humrep/dead184
dc.identifier.eissn1460-2350
dc.identifier.issn0268-1161
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85176413407
dc.identifier.urihttps://doi.org/10.1093/humrep/dead184
dc.identifier.urihttps://hdl.handle.net/20.500.14288/25886
dc.identifier.wos1071172300001
dc.keywordsAdd-on
dc.keywordsGood practice
dc.keywordsGuidelines
dc.keywordsART
dc.keywordsIVF
dc.keywordsICSI
dc.keywordsInfertility
dc.keywordsESHRE
dc.language.isoeng
dc.publisherOxford University Press
dc.relation.grantnoEuropean Society of Human Reproduction and Embryology
dc.relation.ispartofHuman Reproduction
dc.subjectObstetrics and gynecology
dc.subjectReproductive biology
dc.titleGood practice recommendations on add-ons in reproductive medicine
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorBozdağ, Gürkan
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
IR05284.pdf
Size:
1.66 MB
Format:
Adobe Portable Document Format